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Aims: To describe the views of healthcare providers about starting insulin in patients with
type 2 diabetes and to determine the specific factors that contribute to delay insulin initi-
ation.
Methods: Two-phases observational descriptive study. In the quantitative phase we con-
ducted a cross-sectional survey of a sample of 380 healthcare professionals (general prac-
titioners (GPs), endocrinologists, internists and nurses). In the qualitative phase, a
discussion group reviewed the results of the survey to propose solutions.
Results: In poorly controlled patients, 46% of GPs vs. 43.2% of internists and 31.3% of
endocrinologists waited 3–6 months before starting insulin, and 71.4% of GPs vs. 66.7% of
internists vs. 58.8% of endocrinologists need to confirm twice the HbA1c levels. The upper
level of basal glucose more frequently considered as good control is 130 mg/dL for GPs
(35.7%), and 120 mg/dL for internists (35.8%) and endocrinologists (37.5%). In patients with-
out comorbidities, 32.5% of endocrinologists vs. 27.2% of internists vs. 17.9% of GPs initi-
ated insulin when HbA1c was >7% while 26.3% of endocrinologists vs. 28.4% of internists
vs. 38.4% of GPs initiated insulin when HbA1c was >8%. The interference of the therapy
with the patient’ social life and the need for timemanagement were the most accepted bar-
riers to initiate insulin.fonica.net
es@gmail.
lm@gmail.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 2 ( 2 0 1 6 ) 4 6 –5 3 47Conclusions: There are significant differences between GPs and endocrinologists regarding
the insulin initiation and GPs and internists felt less empowered to manage patients with
diabetes. Specific training for professionals and joint work with patients could improve the
glycemic control.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes is currently among the top five causes of death in
most high-income countries and resulted in 4.6 million
deaths globally in 2011 [1]. The prevalence of diabetes, partic-
ularly type 2 (T2DM), continues to grow at an unprecedented
rate [2]. In 2011, 360 million persons had diabetes, of which
95% have T2DM. In 2030, there will be approximately 552 mil-
lion persons with diabetes [3].
Strict glycemic control in T2DM can prevent the onset and
progression of complications [4]. Despite of numerous inter-
ventions to improve adherence to the recommended stan-
dards have been implemented, control is improving, but
slowly [5].
Based on recent large clinical trials there is a growing cur-
rent of opinion that no single hemoglobin A1c (HbA1c) target
is appropriate for all patients. The American Diabetes Associ-
ation (ADA) suggests a fundamentally patient-centered
approach to determine an individual’s HbA1c target. However,
the ADA also recommends a HbA1c target level of less than
7% for the majority of patients [6].
Due to the progressive nature of T2DM, insulin therapy is
eventually indicated for many patients with T2DM [5]. The
progressive nature of T2DM and its therapies should regularly
be explained in a matter-of-fact manner to patients, avoiding
using insulin as a threat or describing it as a failure or punish-
ment [6]. If a patient presents with significant hyperglycemic
symptoms and/or has dramatically elevated plasma glucose
concentrations insulin therapy should be strongly considered
from the outset [7]. But in most patients insulin is prescribed
after combination therapy with metformin and an additional
1–2 oral or injectable agents [7]. When good glycemic control
is not achieved despite other optimal anti-diabetic agents,
insulin should be initiated. But, progression to insulin is fre-
quently delayed, causing unnecessary prolonged periods of
hyperglycemia and preventable complications downstream
[8]. Primary Care is central to addressing this delay in initia-
tion of insulin treatment [9]. Insulin initiation is a complex
social process and this should be reflected in clinical practice
guidelines. A better understanding of the barriers to insulin
initiation in physicians may improve the control of patients
with diabetes control and reduce complications [10]. In Spain,
patients with T2DM are managed by general practitioners
(GPs), endocrinologists or physicians in other specialties as
internists [11]. Internists provide diagnoses and nonsurgical
treatment for a variety of medical conditions and around
40% of patients have diabetes. Most of patients with diabetes
treated by internists are elderly patients with acute or chronic
comorbidity who are admitted to internal medicine due to the
associated pathology or a complication of diabetes. The roleof nurses in helping patients to control T2DM-associatedmor-
bidity and mortality is becoming increasingly important [12].
This study aims to describe the views of GPs, specialists and
diabetes nurses about starting insulin in patients with
T2DM and to determine the specific factors that contribute
to delay insulin initiation among healthcare providers.
2. Material and methods
This observational descriptive study was carried out by using
quantitative and qualitative methods. This multicenter study
was conducted in Spain between September 2012 and April
2013.
2.1. Cross-sectional survey
In the first quantitative phase of the study we conducted a
cross-sectional survey of a national sample of 380 healthcare
professionals who were classified as GPs, endocrinologists,
internists and diabetes nurses from 20 community health
centers and 8 hospitals from the Spanish National Health Sys-
tem. The participants were selected from scientific societies
(family medicine, internal medicine, endocrinology and nurs-
ing) and were invited to participate without personal pres-
ence. Eligibility criteria were: 1) more than 5 years of
experience, 2) responsible for managing diabetes treatment.
This study used snowball sampling, i.e. ‘‘key opinion leaders”
members recruit additional participants. After written
informed consent was obtained, we administered an online
survey to all professionals who accepted.
A structured questionnaire was designed by the coordinat-
ing project group. The online questionnaire consisted of three
parts with 32 questions in total. In the first part of the survey 4
questions about demographic characteristics such as age,
gender and years of experience were asked. The second part
(not for nurses) included questions relating to prescription
habits and treatments as well as questions about the profile
of patients. In the last part of the questionnaire, in order to
assess the theoretical barriers to insulin initiation, partici-
pants were asked how much they agreed to statements
regarding barriers to insulin initiation. These barriers were
identified from previous literature andwere assessed by using
5-point Likert scale (Strongly disagree/Disagree/Not sure/
Agree/Strongly agree). In addition, two multiple choice ques-
tions were asked: (1) About which of the following issues
are you most worried?; (2) When the insulin therapy is initi-
ated, which is the main barrier for patients? We piloted the
instrument before administration of the survey and it was
distributed online on October 2012, with two follow-up
emails.
48 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 2 ( 2 0 1 6 ) 4 6 –5 32.2. Online discussion group
The second phase of the study was qualitative and its objec-
tive was to identify the key topics concerning the barriers to
insulin initiation and then propose solutions make through
the results of the survey by using online discussion group.
We set up a discussion group consisting of four endocrinolo-
gists and four GPs who had at least 10 years of professional
experience treating patients with T2DM, held a leading posi-
tion in diabetes related organizations for science or health
care professionals or had recent publications on aspects of
diabetes care.
We set the duration of discussion sessions to two hours,
and two rounds of comments and revisions were obtained
before the authors reconciled the solutions and edited the
final document. In the first session, discussion group was pro-
vided with the results of the survey and the moderator asked
them an open question: ‘What do you recommend to avoid
the insulin initiation delay?’ The comments and the initial
proposals were analyzed by the coordinating project group
and the insights were redistributed to the discussion group
for comments and assessment. The second session consisted
of one consensus meeting in which the members of the group
discussed their views and reached their conclusions. Based
on the conclusions from the consensus meeting, the coordi-
nating project group edited a final proposal about starting
insulin therapy in patients with T2DM.
2.3. Statistical analysis
Sample size was based on the Spanish statistical database
which estimated a population of 45,000 GPs, endocrinologists,
internists and diabetes nurses in 2011. With a 95% confidence
level, within an error margin of 6%, the sample size require-
ment was 266. In case of a response rate of 70%, a sample
of 380 healthcare professionals is needed. No simple size
was calculated for the discussion group since there is a lack
of agreement around the expert sample size in qualitative
method [13]. A descriptive statistical analysis of the firstTable 1 – Demographic characteristics of the survey responders
Variable GPs Endocrin
N (%) 112 (34.6) 80 (24.8)
Female gender, n (%) 33 (29.5) 32 (40)
Age range in years, mean (SD) 48.8 (4.5) 43.1 (4.1
Type of center, n (%)#
Primary care 81 (72.3) 2 (2.5)
Spec. Amb. Care 10 (8.9) 15 (18.8)
Public hospital 14 (12.5) 58 (72.5)
Private center 25 (22.4) 26 (32.3)
Years of experience, mean (SD) 21.5 (2.2) 16.0 (1.9
Assigned T2DM patients, n (%)
>150 26 (23.2) 58 (72.5)
101–150 35 (31.2) 17 (21.3)
50–100 41 (36.6) 3 (3.8)
<50 10 (8.9) 2 (2.5)
Spec. Amb. Care. : Specialized Ambulatory Care; T2DM: Type 2 Diabete M
# A health provider could choose more than one option.phase results was performed. The qualitative variables are
expressed as the values and percentages, the quantitative
variables as the mean and standard deviation (SD). For the
bivariate analysis, the Chi-square and Student’s t-tests were
used to compare qualitative and quantitative variables
respectively. A p < 0.05 was considered as significant. Confi-
dence intervals of 95% were calculated. There were no miss-
ing data since the incomplete questionnaires were excluded.
Data were analyzed with SPSS 20.0.
2.4. Ethical considerations
All study procedures were approved by the Institutional
Review Board.
3. Results
3.1. Cross-sectional survey
Response rate to the survey was 89.5% (n = 340) and 17 incom-
plete questionnaires were excluded 34.7% (n = 112) of them
were GPs, 24.8% (n = 80) were endocrinologists, 25.1% (n = 81)
were internists and 15.5% (n = 50) were nurses. 79.7% of par-
ticipants worked at public institutions. Demographics of the
cohort stratified by occupation are noted in Table 1. Nurses
answered only the questions which were applicable for them.
Table 2 shows the results of the survey relating to partici-
pants’ opinion about prescription habits for diabetes treat-
ment, including insulin. Regarding the level of HbA1c for
insulin therapy initiation, we asked participants to choose
the best option for older patients with and without comor-
bidities, as the clinical guidelines recommend (Fig. 1).
Regarding participants opinion about the barriers to insu-
lin initiation, the results of the Likert questionnaire are
shown in Fig. 2. And in regard to the two multiple choice
questions, all participant groups chose hypoglycemia (89.5%)
as their most worrying issue and ‘fear of needles’ (64.1%) as
the main patient barrier to insulin initiation without signifi-
cant differences between groups..
ologists Internists Nurses Total
81 (25.1) 50 (15.5) 323 (100.0)
24 (29.6) 43 (86) 124 (38.4)
) 43.3 (4.2) 47.3 (4.7) 47.3 (4.0)
2 (2.5) 32 (63.6) 204 (63.3)
7 (8.6) 5 (36.4) 36 (11.2)
71 (87.7) 17 (36.4) 74 (22.9)
17 (20.9) 10 (18.2) 71 (22.2)
) 16.1 (2.1) 17.1 (3.1) 20.2 (2.2)
32 (39.5) 19 (38) 91 (28.1)
23 (28.4) 9 (18) 93 (28.7)
20 (24.7) 13 (26) 107 (33.2)
6 (7.4) 9 (18) 33 (10.1)
ellitus; GPs: General practitioners.
Table 2 – Results of the survey relating to prescription habits and treatments.
GPs N = 112 Endocrinologists N = 80 Internists N = 81 p-Value
Which diabetes guidelines do you often use?
ADA-EASD 48.2* 78.8 74.1 <0.05
RedGEDAPS 30.4* 7.5 9.9 <0.05
SED 23.2 48.8* 33.3 <0.05
Other 12.5 31.4 13.6
None 21.4 3.8* 12.3 <0.05
After failure with metformin, which treatment do you often use?
DPP-4 inhibitors 58.0* 72.5 75.3 <0.05
Sulfonylureas 28.6 25.0 17.3* <0.05
GLP-1 RA 18.8 28.8 16.0
Insulin 17.9 16.3 24.7
Other 25.9 8.8 19.7
After oral therapy failure with two agents, which treatment do you often use?
Insulin 70.5 52.5* 69.1 <0.05
DPP-4 inhibitors 17.9 12.5 14.8
Sulfonylureas 14.3 21.3 11.1
GLP-1 RA 7.1* 25.0 21.0 <0.05
Other 16.1 17.6 13.5
If the oral therapy does not achieve target levels, how long it takes to start insulin therapy?
1–2 years 0.9 0.0 0.0
6 months–1 year 9.8 6.3 3.7
3–6 months 46.4 31.3 43.2
<3 months 42.9* 62.5 53.1 <0.05
Before insulin initiation, how many times do you confirm HbA1c level?
Three times 13.4* 0.0 2.5 <0.05
Twice 71.4* 58.8 66.7 <0.05
One 15.2* 41.3 30.9 <0.05
Which type of insulin do you use to initiate the treatment?
Glargine 54.1 63.8 66.7
NPH 21.4* 5.0 6.4 <0.05
Detemir 17.3 23.8 19.2
Mixture 6.1 7.5 5.1
Rapid-acting analog 1.0 0.0 2.6
Which basal insulin dose do you use when you initiate insulin therapy?
0.2 U/kg b.w 33.9* 61.3 49.4 <0.05
0.1 U/kg b.w 36.6 16.3* 28.4 <0.05
10 U 20.5 15.0 14.8
According to patient 2.7 1.3 2.5
Other 6.2 6.3 4.9
Which upper limit of fasting blood glucose do you use as good control target in insulin treated patients?
100 mg/dL 5.4 16.3 7.4
120 mg/dL 24.1 37.5 35.8
130 mg/dL 35.7 32.6 19.8
140 mg/dL 32.1 13.8* 34.6 <0.05
>140 mg/dL 2.7 0.0 2.5
ADA-EASD: American Diabetes Association-European Association for the Study of Diabetes; RedGEDAPS Primary Care Diabetes Spanish
Guideline; SED: Spanish Society of Diabetes Guideline; GLP-1 RA: Glucagon-like peptide-1 receptor agonists; NPH: Neutral Protamine Hagedorn;
b.w.: body weight.
* It is significantly different.
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The eight members of the discussion group attended the
online meetings. In the first session, in order to avoid the
insulin initiation delay, the discussion group made recom-
mendations as follows: (1) it is necessary a specific training
for physicians and diabetes nurses in primary care setting
who showed to have concerns regarding the managementof insulin treatment; (2) HbA1c test every 3 months should
be done in patients with poorly controlled T2DM; (3) to set
personalized targets is recommended but there should be
no significant differences between GPs and specialists; (4)
the optimization of insulin dose is more important than the
initial dose and; (5) to overcome the preconceived ideas of
the patients about insulin therapy, care providers must work
with them from the beginning of the disease.
Fig. 1 – Level of hemoglobin HbA1c to initiate insulin therapy in older patients.
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group, a summary of the proposals were sent to the discus-
sion group. In the second session, members of the discussion
group took in account the differences between GPs, endocri-
nologists and internists when they manage the insulin initia-
tion and that the survey results revealed that less than 50% of
GPs and internists agreed that the insulin is more effective
than oral therapy. They made recommendations as follow:
(1) specific and consensual training for all professionals who
manage patients with diabetes; (2) to reinforce insulin ther-
apy as the most effective treatment; (3) to add basal insulin
to OAD for early glycemic control and; (4) to work jointly with
associations to improve patient education.
Finally, the coordinating project group reviewed the results
of the second session and group edited a final proposal about
starting insulin therapy in patients with T2DM (Table 3).
4. Discussion
This study showed how healthcare providers manage T2DM
during their daily practice and the findings illustrated
differences between GPs, endocrinologists and internists. In
addition, the barriers to initiate insulin therapy in patients
with T2DM were analyzed and healthcare providers agreedin some barriers: to consider insulin as the last resort, the side
effects, thinking insulin is ‘dangerous’ or the insulin inter-
feres with patient’s social life. However, they considered insu-
lin as the most effective therapy and did not think that ‘basal
insulin therapy is difficult’.
The findings of this study showed that the ADA-EASD was
the most used guideline bymost of participants as a reference
guide for the treatment of T2DM (Table 2), especially by
endocrinologists and GPs. The relationship of guideline use
to diabetes-related knowledge and decision making by provi-
ders has not been formally described in previous studies but it
may help to identify areas of need for further training and
continuing diabetes education [14]. Studies on guidelines
implementation among Spanish professionals found primary
care physicians tended to implement guidelines-more closely
related to their field of medical practice while specialists
tended to use the guidelines of specialized national or inter-
national scientific societies [15].
Our results showed that GPs takemore time to start insulin
than other specialists and need to confirm levels of HbA1c
more times. In patients with poor glycaemic control, most of
GPs waited more than 3 months before insulin therapy is
initiated and confirmed twice HbA1c measures. Initiation
of insulin therapy was frequently delayed for many
Fig. 2 – Agreement and disagreement regarding barriers to insulin initiation.
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number of surveys [16–18]. Previous research found that the
mean time to initiate insulin was 9.2 years since T2DM diag-
nosis and themean HbA1c value was 9.5% before insulin initi-
ation [19]. Another study suggested that some GPs had beliefs
about insulin that were inconsistent with their diabetes treat-
ment goals [20]. Agarwal et al. stated that many GPs felt pro-
viding diabetes care caused a high clinical burden and
increased the need for greater vigilance. The lack of experi-
ence made some apprehensive about insulin initiation [21].
Furler et al. suggested thatmany GPs delayed a decision to ini-
tiate insulin, as the process of initiating insulin is not congru-
ent with their usual work practices. By contrast, a Canadian
survey found that GPs used higher doses of insulin than other
specialists who used oral therapy longer [22]. Clarification inTable 3 – Summary of the solutions proposed by the discussion
Challenges of insulin initiation
To set personalized targets reminding the current targets recom
To recommendHbA1c test every 3 months in patients with poor
Patients may benefit from early treatment with basal insulin ad
control (metabolic memory can reduce complications)
To reinforce insulin therapy as the most effective treatment
To initiate insulin therapy with basal insulin reaching for optim
Towork jointly with patients and associations to improve educat
therapy
Specific training for physicians and diabetes nurses with clear a
overcome inertia and barriersthe roles of each health professional in initiating insulin
may be an important prerequisite for therapeutic progress
and clinical guidelines for T2DM care in general practicemake
little direct reference to this issue [10].
In this study (Fig. 1), in patients with comorbidities, GPs
and internists chose to initiate insulin therapy at lower level
of HbA1c than endocrinologists despite the guidelines recom-
mendations [5–7,23,24]. Otherwise in patients without comor-
bidities, endocrinologists preferred to initiate insulin therapy
at a lower level of HbA1c than GPs and internists. This topic
must be confirmed or not with other studies as there was
no consensus between healthcare providers and it is very
important to be less aggressive in patients with comorbidities
where the objective of prevention of complications could be
impossible.group.
mended by guidelines
ly controlled Type 2 diabetes and take action
ded to oral antidiabetic drug (OAD) through early glycemic
al dose. Optimization is more important than initial dose
ion and overcome barriers and preconceived ideas about insulin
nd well defined concepts that enable action and help to
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the therapy with insulin interferes with patient’s social life
and that the insulin treatment consultations are more time-
consuming were the most accepted barriers by the partici-
pants of this survey research. Diabetes nurses were the group
who felt the most concern about these issues. Practice nurses
could play a key role in facilitating the initiation of insulin in
general practice [10] and in hospitals. Nurses can screen
patients for early diabetes identification, recognize and initi-
ate corrective measures for inadequate treatment regimens,
help patients set and achieve therapeutic goals, and assess
diabetes-related complications as they arise [12]. In regard
to capability, all professionals (GPs, endocrinologists and
internists) considered that to initiate basal insulin therapy
or to follow-up patients treated with insulin is not difficult.
However, our findings illustrated GPs and internists felt less
empowered to manage these patients and think that the
multiple-dose insulin regimens are difficult to manage.
Previous studies have suggested that barriers to insulin
initiation lie in ‘psychological resistance’: health providers’
incomplete knowledge of the rationale and belief in the safety
of starting insulin and patient fears and misconceptions
[25,26]. This study identified that barriers to insulin initiation
also occur because of patient resistance and it is thought the
main patient barrier to insulin initiation is ‘‘fear of needles”.
Providers, on the other hand, accepted they may fear hypo-
glycemia and had concern for their patients’ safety. Similarly,
in another study the major reasons cited by physicians were
concerns about patients’ ability to comply with therapy, as
well as the risks of hypoglycaemia associated with insulin
therapy. About patient reasons, ‘‘dreading take their injec-
tions” appeared as the main cause [27].
In the qualitative phase of the study (Table 3), the expert
group highlighted the importance of individual’s HbA1c tar-
gets as guidelines recommend. As there was no consensus
about HbA1c target level, one reason could be that the guide-
lines are poorly understood or deemed unreliable. New
themes emerging from the discussion group included the
importance of working jointly with patients and associations.
Recent publications found that most of adverse events in
patients with diabetes have been attributed to physician–pa-
tient communication problems [28]. To overcome the psycho-
logical insulin resistance experienced by the patient, it is
important to begin the conversation early and talk about dia-
betes as a progressive disease that eventually most people
with T2DM will require insulin to achieve normal blood glu-
cose [27].
The expert group requested training for physicians and
diabetes nurses in order to clarify doubts about monitoring
patients with diabetes (dose adjustments, intensification of
therapy and therapeutic education for patients) and to
empower the decision of GPs to initiate insulin therapy and
patient acceptance through shared decision-making. Health-
care professionals should be trained how to initiate insulin
and communicate effectively with patients from various cul-
tural and religious backgrounds [29]. The lack of consensus
about diabetes management emphasizes the necessity of
medical education programs that increase knowledge about
diabetes and about the physiological effects of insulin.4.1. Strengths and limitations
This study showed the views of different healthcare providers
who attend patients with T2DM. Individual surveys generally
cannot provide strong evidence of cause and effect but they
allow exploring aspects of a situation, or to seek explanation
and provide data for testing hypotheses. In addition, there
was a lack of concordance among healthcare providers in sev-
eral questions of the quantitative phase. This may be because
each professional group sees patients with different charac-
teristics or in different stages of the evolution of the disease.
Regarding the qualitative phase, this research is limited in
that it represents the opinions and consensus of a group
and has all the typical limitations of expert panels. The
results may be biased due to the snowball recruitment strat-
egy since the sample might include an over-representation of
individuals with similar characteristics. In addition, the opin-
ion of professionals might fluctuate due to new evidence and
knowledge and future revisions may significantly change the
recommendations. However, this kind of study allows know-
ing the professional ‘opinion which determines the
prescriptions.
This study reports the opinion of the healthcare providers
in regard to the insulin therapy. However, further research is
needed to know the views of patients with diabetes.
After knowing the possible reasons to delay insulin ther-
apy, the national health system should take action to over-
come them and, thus, the control of patients with T2DM
would improve and consequently, the complications and
costs involved in resolving them might be reduced.
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